Altimmune securities

Search documents
ALT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT
Globenewswireยท 2025-09-27 18:58
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors must move the Court by October 6, 2025, to serve as lead plaintiff, representing other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Background - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4] - Altimmune is accused of inflating expectations for positive results while concealing adverse data from the placebo group, leading to investor damages when the true results were revealed [4]